PD1 signal transduction pathways in T cells

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very...

Descripción completa

Detalles Bibliográficos
Autores: Arasanz Esteban, Hugo, Gato Cañas, María, Zuazo Ibarra, Miren, Ibañez Vea, María, Breckpot, Karine, Kochan, Grazyna, Escors Murugarren, David
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/43708
Acceso en línea:https://hdl.handle.net/2454/43708
Access Level:acceso abierto
Palabra clave:PD-L1
PDL1
PD1
B7-H1
Cancer
id ES_366e5e5c5e2d815936204372df8f8753
oai_identifier_str oai:academica-e.unavarra.es:2454/43708
network_acronym_str ES
network_name_str España
repository_id_str
spelling PD1 signal transduction pathways in T cellsArasanz Esteban, HugoGato Cañas, MaríaZuazo Ibarra, MirenIbañez Vea, MaríaBreckpot, KarineKochan, GrazynaEscors Murugarren, DavidPD-L1PDL1PD1B7-H1CancerThe use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.MGC is funded by a Government of Navarre PhD fellowship (BMED 033-2014); MZ is funded by a Gobierno de Navarra Project grant (GN 33/14) and a ‘Precipita’ crowdfunding project grant from Fundación Española para la Ciencia y la Tecnología (FECYT). MIV is funded by a Sara Borrel post-doctoral fellowship. DE is funded by a 'Miguel Servet' Fellowship (CP12/03114) from the Instituto de Salud Carlos III (ISCIII), Spain. GK is funded by a ‘Proyecto Tractor ProCel’ from the Government of Navarre. The authors gratefully acknowledge the ‘Sandra Ibarra’ Foundation, the ‘Navarrese Association against Breast Cancer’ (SARAY), ‘Caixa Foundation’ and ISCIII (FIS. PI14/00579 project grant) for their financial support.Impact JournalsCiencias de la SaludOsasun ZientziakGobierno de Navarra / Nafarroako Gobernua2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2454/43708reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarrainstname:Universidad Pública de NavarraInglés© Arasanz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0https://creativecommons.org/licenses/by/3.0/info:eu-repo/semantics/openAccessoai:academica-e.unavarra.es:2454/437082026-06-17T12:41:47Z
dc.title.none.fl_str_mv PD1 signal transduction pathways in T cells
title PD1 signal transduction pathways in T cells
spellingShingle PD1 signal transduction pathways in T cells
Arasanz Esteban, Hugo
PD-L1
PDL1
PD1
B7-H1
Cancer
title_short PD1 signal transduction pathways in T cells
title_full PD1 signal transduction pathways in T cells
title_fullStr PD1 signal transduction pathways in T cells
title_full_unstemmed PD1 signal transduction pathways in T cells
title_sort PD1 signal transduction pathways in T cells
dc.creator.none.fl_str_mv Arasanz Esteban, Hugo
Gato Cañas, María
Zuazo Ibarra, Miren
Ibañez Vea, María
Breckpot, Karine
Kochan, Grazyna
Escors Murugarren, David
author Arasanz Esteban, Hugo
author_facet Arasanz Esteban, Hugo
Gato Cañas, María
Zuazo Ibarra, Miren
Ibañez Vea, María
Breckpot, Karine
Kochan, Grazyna
Escors Murugarren, David
author_role author
author2 Gato Cañas, María
Zuazo Ibarra, Miren
Ibañez Vea, María
Breckpot, Karine
Kochan, Grazyna
Escors Murugarren, David
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ciencias de la Salud
Osasun Zientziak
Gobierno de Navarra / Nafarroako Gobernua
dc.subject.none.fl_str_mv PD-L1
PDL1
PD1
B7-H1
Cancer
topic PD-L1
PDL1
PD1
B7-H1
Cancer
description The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2454/43708
url https://hdl.handle.net/2454/43708
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname:Universidad Pública de Navarra
instname_str Universidad Pública de Navarra
reponame_str Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
collection Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405957921964032
score 15,81155

Similares en LA Referencia